Ozempic European Medicines Agency EPAR
The most significant clinical data on retatrutide to date come from its Phase 2 trials, published in the New England Journal of Medicine in 2023
Medical supervision improves safety, side effect management, and long-term success
INFORMATION What is Retatrutide (10 mg)
Adult Obesity Facts, CDC Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial, Obesity (2020) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity, The New England Journal of Medicine (2023) GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects, Frontiers in Endocrinology (2021) Wegovy: Understanding list price, NovoCare How much should I expect to pay for Mounjaro?, Lilly (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
may escalate to 14 mg based on response Must be taken on an empty stomach with a small sip of water (120 ml) and wait 30 minutes before eating, drinking or taking other oral medicines For semaglutide (Wegovy) used in weight management: Gradual escalation over 1620 weeks, starting at 0.25 mg weekly Target maintenance dose: 2.4 mg once weekly Some patients may remain on 1.7 mg if 2.4 mg is not tolerated For dulaglutide (Trulicity) : Starting dose: 0.75 mg once weekly Can be increased to 1.5 mg, 3 mg, or 4.5 mg weekly depending on response For liraglutide (Victoza) in diabetes: Starting dose: 0.6 mg daily for at least one week Maintenance: 1.2 mg daily, with possible increase to 1.8 mg For liraglutide (Saxenda) in weight management: Gradual weekly increases from 0.6 mg to a target of 3 mg daily All GLP-1 medications follow a dose-escalation protocol to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea
